{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:44:17Z","timestamp":1787024657523,"version":"build-2736575974"},"reference-count":56,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CNSNDDT"],"published-print":{"date-parts":[[2019,2,21]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Bipolar Disorder (BD) is a psychiatric disorder characterized by mood disturbances. The pathophysiology of BD is still poorly understood. In the last years, research studies focused on the role of inflammation in BD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Performed a systematic review and meta-analysis to evaluate the potential effect of the cyclo- oxygenases (Cox)-2 inhibitor Celecoxib adjunct treatment in BD through randomized controlled trials (RCT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A search on the electronic databases was proceeded, on MEDLINE, EMBASE, Scopus, Cochrane Central Register of Controlled Trials (CENTRAL), Biomed Central, Web of Science, IBECS, LILACS, PsycINFO, Congress Abstracts, and Grey literature (Google Scholar and the British Library) for studies published from January 1990 to February 2018. A search strategy was developed using the terms: \u201cBipolar disorder\u201d or \u201cBipolar mania\u201d or \u201cBipolar depression\u201d or \u201cBipolar mixed\u201d or \u201cBipolar euthymic\u201d and \u201cCelecoxib\u201d or \u201cCyclooxygenase-2 inhibitors\u201d or \u201cCox-2 inhibitors\u201d as text words and Medical Subject Headings (i.e., MeSH and EMTREE) and searched. The therapeutic effects of adjunctive treatment with Celecoxib were analyzed. The meta-analysis was performed including the results of the Young Mania Rating Scale (YMRS) at the end of RCT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Three primary studies were included in the systematic review, with a total of 121 patients. The meta-analysis showed a significant effect on the YMRS scores from patients with BD who used Celecoxib adjuvant treatment in comparison to placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The systematic review suggests that adjuvant treatment with Celecoxib improves the response of major treatments in patients with BD when compared with adjuvant placebo treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration Number:<\/jats:title>\n                    <jats:p>The review protocol was registered at PROSPERO (registration number: CRD42017067635); in June 06 2017.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1871527317666181105162347","type":"journal-article","created":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T23:40:32Z","timestamp":1541547632000},"page":"19-28","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Efficacy of Celecoxib Adjunct Treatment on Bipolar Disorder: Systematic Review and Meta-Analysis"],"prefix":"10.2174","volume":"18","author":[{"given":"Daniela V.","family":"Bavaresco","sequence":"first","affiliation":[{"name":"Translational Biomedicine Laboratory, Graduate Program in Health Sciences, University of Southern Santa Catarina (UNESC), Criciuma, SC, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamy","family":"Colonetti","sequence":"additional","affiliation":[{"name":"Translational Biomedicine Laboratory, Graduate Program in Health Sciences, University of Southern Santa Catarina (UNESC), Criciuma, SC, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ant\u00f4nio J.","family":"Grande","sequence":"additional","affiliation":[{"name":"Laboratorio de Evidencias em Saude, Mestrado Profissional Ensino em Saude, Universidade Estadual de Mato Grosso do Sul, MS, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Colom","sequence":"additional","affiliation":[{"name":"Mental Health Group, IMIM-Hospital del Mar-CIBERSAM, Barcelona-Catalonia, Barcelona, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira S.","family":"Valvassori","sequence":"additional","affiliation":[{"name":"Translational Psychiatry Laboratory, Graduate Program in Health Sciences, University of Southern Santa Catarina (UNESC), Criciuma, SC, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Quevedo","sequence":"additional","affiliation":[{"name":"Translational Psychiatry Laboratory, Graduate Program in Health Sciences, University of Southern Santa Catarina (UNESC), Criciuma, SC, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria I.","family":"da Rosa","sequence":"additional","affiliation":[{"name":"Translational Biomedicine Laboratory, Graduate Program in Health Sciences, University of Southern Santa Catarina (UNESC), Criciuma, SC, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","author":"","year":"","unstructured":".","journal-title":"American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2013;"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1176\/appi.ajp.163.2.210","volume":"163","author":"Nierenberg A.A.","year":"2006","unstructured":"Nierenberg AA, Ostacher MJ, Calabrese JR. Treatment-resistant bipolar depression: A STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone.","journal-title":"Am J Psychiatry"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1176\/ajp.2006.163.9.1561","volume":"163","author":"Kessler R.C.","year":"2006","unstructured":"Kessler RC, Akiskal HS, Ames M, Birnbaum H, Greenberg P, Hirschfeld RM. Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers.","journal-title":"Am J Psychiatry"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1590\/1516-4446-2012-1693","volume":"37","author":"Clemente A.S.","year":"2015","unstructured":"Clemente AS, Diniz BS, Nicolato R. Bipolar disorder prevalence: A systematic review and meta-analysis of the literature.","journal-title":"Rev Bras Psiquiatr"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00787-014-0614-z","volume":"23","author":"Serafini G.","year":"2014","unstructured":"Serafini G, Pompili M, Borgwardt S. Brain changes in early-onset bipolar and unipolar depressive disorders: A systematic review in children and adolescents.","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.neubiorev.2014.02.004","volume":"42","author":"Rizzo L.B.","year":"2014","unstructured":"Rizzo LB, Costa LG, Mansur RB. The theory of bipolar disorder as an illness of accelerated aging: Implications for clinical care and research.","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000356539","volume":"21","author":"Barbosa I.G.","year":"2014","unstructured":"Barbosa IG, Machado-Vieira R, Soares JC, Teixeira AL. The immunology of bipolar disorder.","journal-title":"Neuroimmunomodulation"},{"key":"ref=8","first-page":"360","author":"Barbosa I.G.","year":"2014","unstructured":"Barbosa IG, Bauer ME, Machado-Vieira R, Teixeira AL. Cytokines in bipolar disorder: Paving the way for neuroprogression.","journal-title":"Neural Plast"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.neubiorev.2010.10.001","volume":"35","author":"Berk M.","year":"2011","unstructured":"Berk M, Kapczinski F, Andreazza AC. Pathways underlying neuroprogression in bipolar disorder: Focus on inflammation, oxidative stress and neurotrophic factors.","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/mp.2009.47","volume":"15","author":"Rao J.S.","year":"2010","unstructured":"Rao JS, Harry GJ, Rapoport SI, Kim HW. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients.","journal-title":"Mol Psychiatry"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.biopsych.2013.01.007","volume":"74","author":"Modabbernia A.","year":"2013","unstructured":"Modabbernia A, Taslimi S, Brietzke E, Ashrafi M. Cytokine alterations in bipolar disorder: A meta-analysis of 30 studies.","journal-title":"Biol Psychiatry"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.jpsychires.2013.05.018","volume":"47","author":"Munkholm K.","year":"2013","unstructured":"Munkholm K, Bra\u00fcner JV, Kessing LV, Vinberg M. Cytokines in bipolar disorder healthy control subjects: A systematic review and meta-analysis.","journal-title":"J Psychiatr Res"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1089\/vim.2005.18.41","volume":"18","author":"Silverman M.N.","year":"2005","unstructured":"Silverman MN, Pearce BD, Biron CA, Miller AH. Immune modulation of the hypothalamic-pituitary-adrenal (HPA) axis during viral infection.","journal-title":"Viral Immunol"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S0140-6736(13)60857-0","volume":"381","author":"Geddes J.R.","year":"2013","unstructured":"Geddes JR, Miklowitz DJ. Treatment of bipolar disorder.","journal-title":"Lancet"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00004850-200015040-00001","volume":"15","author":"Soares J.C.","year":"2000","unstructured":"Soares JC. Recent advances in the treatment of bipolar mania, depression, mixed states, and rapid cycling.","journal-title":"Int Clin Psychopharmacol"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/da.22479","volume":"33","author":"Ketter T.A.","year":"2016","unstructured":"Ketter TA, Sarma K, Silva R, Kroger H, Cucchiaro J, Loebel A. Lurasidone in the long-term treatment of patients with bipolar disorder: A 24-week open-label extension study.","journal-title":"Depress Anxiety"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/bdi.12503","volume":"19","author":"Valvassori S.S.","year":"2017","unstructured":"Valvassori SS, Resende WR, Dal-Pont G. Lithium ameliorates sleep deprivation-induced mania-like behavior, hypothalamic-pituitary-adrenal (HPA) axis alterations, oxidative stress and elevations of cytokine concentrations in the brain and serum of mice.","journal-title":"Bipolar Disord"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/bdi.12299","volume":"17","author":"Valvassori S.S.","year":"2015","unstructured":"Valvassori SS, Tonin PT, Varela RB. Lithium modulates the production of peripheral and cerebral cytokines in an animal model of mania induced by dextroamphetamine.","journal-title":"Bipolar Disord"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/bdi.12324","volume":"17","author":"Arabzadeh S.","year":"2015","unstructured":"Arabzadeh S, Ameli N, Zeinoddini A. Celecoxib adjunctive therapy for acute bipolar mania: A randomized, double-blind, placebo-controlled trial.","journal-title":"Bipolar Disord"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1177\/0269881117725711","volume":"31","author":"Husain M.I.","year":"2017","unstructured":"Husain MI, Strawbridge R, Stokes PR, Young AH. Anti-inflammatory treatments for mood disorders: Systematic review and meta-analysis.","journal-title":"J Psychopharmacol"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1089\/cap.2016.0207","volume":"27","author":"Mousavi S.Y.","year":"2017","unstructured":"Mousavi SY, Khezri R, Karkhaneh-Yousefi MA. Randomized double-blind placebo-controlled trial on effectiveness and safety of celecoxib adjunctive therapy in adolescents with acute bipolar mania.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"22903","DOI":"10.1074\/jbc.274.33.22903","volume":"274","author":"Marnett L.J.","year":"1999","unstructured":"Marnett LJ, Rowlinson WS, Goodwin DC, Kalgutkar AS, Lanzo CA. Arachidonic acid oxygenation by COX-1 and COX-2.","journal-title":"J Biol Chem"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/rheumatology\/38.8.779","volume":"38","author":"Brooks P.","year":"1999","unstructured":"Brooks P, Emery P, Evans JF. Interpreting the clinical significance of the diferential inhibition of cyclooxygenase-1 and cyclooxygenase-2.","journal-title":"Rheumatology"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0002-9343(01)00757-4","volume":"111","author":"Perazella M.A.","year":"2001","unstructured":"Perazella MA, Tray K. Selective cyclooxygenase-2 inhibitors: A pattern of nephrotoxicity similar to traditional nosteroidal anti-inflammatory drugs.","journal-title":"Am J Med"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.1523\/JNEUROSCI.21-16-05847.2001","volume":"21","author":"Yaksh T.L.","year":"2001","unstructured":"Yaksh TL, Dirig DM, Conway CM, Svensson C, Luo ZD, Isakson PC. The acute antihyperalgesic action of nonsteroidal, anti-inflammatory drugs and release of spinal prostaglandin E2 is mediated by the inhibition of constitutive spinal cyclooxygenase-2 (COX-2) but not COX-1.","journal-title":"J Neurosci"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0002-9343(00)00681-1","volume":"110","author":"Cannon G.W.","year":"2001","unstructured":"Cannon GW, Breedveld FC. Efficacy of cyclooxygenase-2 specific inhibitors.","journal-title":"Am J Med"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"Liberati A.","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J. The PRISMA statement for reporting systematic review and meta-analysis of studies that evaluate healthcare interventions: Explanation and elaboration.","journal-title":"BMJ"},{"key":"ref=28","author":"","year":"","unstructured":"."},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"Dersimonian R.","year":"1986","unstructured":"Dersimonian R, Laird N. Meta-analysis in clinical trials.","journal-title":"Control Clin Trials"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"w13880","DOI":"10.4414\/smw.2014.13880","volume":"144","author":"Kargar M.","year":"2014","unstructured":"Kargar M, Yousefi A, Mojtahedzadeh M. Effects of celecoxib on inflammatory markers in bipolar patients undergoing electroconvulsive therapy: A placebo-controlled, double-blind, randomised study.","journal-title":"Swiss Med Wkly"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1055\/s-0035-1559667","volume":"48","author":"Kargar M.","year":"2015","unstructured":"Kargar M, Yoosefi A, Akhondzadeh S, Artonian V, Ashouri A, Ghaeli P. Effect of adjunctive celecoxib on BDNF in manic patients undergoing electroconvulsive therapy: A randomized double blind controlled trial.","journal-title":"Pharmacopsychiatry"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hup.912","volume":"23","author":"Nery F.G.","year":"2008","unstructured":"Nery FG, Monkul ES, Hatch JP. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: A double-blind, randomized, placebo-controlled study.","journal-title":"Hum Psychopharmacol"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","volume":"343","author":"Sterne J.A.","year":"2011","unstructured":"Sterne JA, Sutton AJ, Ioannidis JP. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomized controlled trials.","journal-title":"BMJ"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jad.2012.02.016","volume":"140","author":"Brietzke E.","year":"2012","unstructured":"Brietzke E, Mansur RB, Soczynska JK, Kapczinski F, Bressan RA, McIntyre RS. Towards a multifactorial approach for prediction of bipolar disorder in at risk populations.","journal-title":"J Affect Disord"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.neuroscience.2015.03.007","volume":"19","author":"Barrientos R.","year":"2015","unstructured":"Barrientos R, Kitt MM, Watkins LR, Maier SF. Neuroinflammation in the normal aging hippocampus.","journal-title":"Neuroscience"},{"key":"ref=36","first-page":"29","volume":"21","author":"Lima R.R.","year":"2007","unstructured":"Lima RR, Costa AMR, Souza RD, Gomesleal W. Inflamation in neurodegenerative disease.","journal-title":"Rev Para Med"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.biopsych.2007.05.026","volume":"62","author":"Felger J.C.","year":"2007","unstructured":"Felger JC, Alagbe O, Hu F. Effects of interferon-alpha on rhesus monkeys: A nonhuman primate model of cytokine-induced depression.","journal-title":"Biol Psychiatry"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.biopsych.2008.11.029","volume":"65","author":"Miller A.H.","year":"2009","unstructured":"Miller AH, Maletic V, Raison CL. Inflammation and its discontents: The role of cytokines in the pathophysiology of major depression.","journal-title":"Biol Psychiatry"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/da.22084","volume":"30","author":"Miller A.H.","year":"2013","unstructured":"Miller AH, Haroon E, Raison CL, Felger JC. Cytokine targets in the brain: Impact on neurotransmitters and neurocircuits.","journal-title":"Dep Anx"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.intimp.2016.03.014","volume":"35","author":"Zambalde \u00c9.P.","year":"2016","unstructured":"Zambalde \u00c9P, Teixeira MM, Favarin DC. The anti-inflammatory and pro-resolution effects of aspirin-triggered RvD1 (AT-RvD1) on peripheral blood mononuclear cells from patients with severe asthma.","journal-title":"Int Immunopharmacol"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.brainresrev.2007.02.003","volume":"55","author":"Goncharova L.B.","year":"2007","unstructured":"Goncharova LB, Tarakanov AO. Molecular networks of brain and immunity.","journal-title":"Brain Res Rev"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2174\/157339510791823673","volume":"6","author":"Muller N.","year":"2010","unstructured":"Muller N, Schwarz MJ. Immune system and schizophrenia.","journal-title":"Curr Immunol Rev"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1590\/S0047-20852009000100009","volume":"58","author":"Barbosa I.G.","year":"2009","unstructured":"Barbosa IG, Huguet RB, Neves FS, Bauer ME, Teixeira AL. Immunology of bipolar disorder.","journal-title":"J Bras Psiquiatr"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jad.2012.03.033","volume":"141","author":"Abbasi S.H.","year":"2012","unstructured":"Abbasi SH, Hosseini F, Modabbernia A, Ashrafi M, Akhondzadeh S. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: Randomized double-blind placebo-controlled study.","journal-title":"J Affect Disord"},{"key":"ref=45","first-page":"647","volume":"32","author":"Chen C.Y.","year":"2010","unstructured":"Chen CY, Tzeng NS, Chen YC. Maintenance therapy of celecoxib for major depression with mimicking neuropsychological dysfunction.","journal-title":"Gen Hosp Psychiatry"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/hup.2401","volume":"29","author":"Faridhosseini F.","year":"2014","unstructured":"Faridhosseini F, Sadeghi R, Farid L, Pourgholami M. Celecoxib: A new augmentation strategy for depressive mood episodes. A systematic review and meta-analysis of randomized placebo-controlled trials.","journal-title":"Hum Psychopharmacol"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.bbr.2012.07.007","volume":"234","author":"Borre Y.","year":"2012","unstructured":"Borre Y, Lemstra S, Westphal KG, Morgan ME, Olivier B, Oosting RS. Celecoxib delays cognitive decline in an animal model of neurodegeneration.","journal-title":"Behav Brain Res"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/jnr.10192","volume":"68","author":"Casolini P.","year":"2002","unstructured":"Casolini P, Catalani A, Zuena AR, Angelucci L. Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat.","journal-title":"J Neurosci Res"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1124\/jpet.301.2.494","volume":"301","author":"Mirjany M.","year":"2002","unstructured":"Mirjany M, Ho L, Pasinetti GM. Role of cyclooxygenase-2 in neuronal cell cycle activity and glutamate-mediated excitotoxicity.","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.it.2005.11.006","volume":"27","author":"Raison C.L.","year":"2006","unstructured":"Raison CL, Capuron L, Miller AH. Cytokines sing the blues: Inflammation and the pathogenesis of depression.","journal-title":"Trends Immunol"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0014-2999(02)02104-0","volume":"450","author":"Ross B.M.","year":"2002","unstructured":"Ross BM, Brooks RJ, Lee M. Cyclooxygenase inhibitor modulation of dopamine-related behaviours.","journal-title":"Eur J Pharmacol"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.jpsychires.2011.08.003","volume":"45","author":"Hope S.","year":"2011","unstructured":"Hope S, Dieset I, Agartz I. Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia.","journal-title":"J Psychiatr Res"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/NDT.S115002","volume":"13","author":"Husain M.I.","year":"2016","unstructured":"Husain MI, Chaudhry IB, Hamirani MM. Minocycline and celecoxib as adjunctive treatments for bipolar depression: A study protocol for a multicenter factorial design randomized controlled trial.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jad.2012.11.033","volume":"147","author":"Subramaniam M.","year":"2013","unstructured":"Subramaniam M, Abdin E, Vaingankar JA. Impact of psychiatric disorders and chronic physical conditions on health-related quality of life: Singapore mental health study.","journal-title":"J Affect Disord"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"e91936","DOI":"10.1371\/journal.pone.0091936","volume":"29","author":"Ferrari A.J.","year":"2014","unstructured":"Ferrari AJ, Norman RE, Freedman G. The burden attributable to mental and substance use disorders as risk factors for suicide: Findings from the Global Burden of Disease Study 2010.","journal-title":"PLoS One"},{"key":"ref=56","author":"Garc\u00eda-Rayado G.","year":"2018","unstructured":"Garc\u00eda-Rayado G, Navarro M. Lanas A4. NSAID induced gastrointestinal damage and designing GI-sparing NSAIDs.","journal-title":"Expert Rev Clin Pharmacol"}],"container-title":["CNS &amp; Neurological Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/167057","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:11:28Z","timestamp":1775261488000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/167057\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,21]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2,21]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871527317666181105162347","relation":{},"ISSN":["1871-5273"],"issn-type":[{"value":"1871-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2,21]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-06-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-06","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}